Lv3
256 积分 2023-08-03 加入
Cabozantinib exposure–response analyses of efficacy and safety in patients with advanced hepatocellular carcinoma
11天前
已完结
Lenvatinib: A Review in Hepatocellular Carcinoma
11天前
已完结
Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study
16天前
已完结
The Role of Quantitative Systems Pharmacology in the Design of First‐in‐Human Trials
1个月前
已完结
Comparison of the urinary glucose excretion contributions of SGLT2 and SGLT1: A quantitative systems pharmacology analysis in healthy individuals and patients with type 2 diabetes treated with SGLT2 inhibitors
1个月前
已完结
A Framework for Quantitative Systems Pharmacology Model Execution
1个月前
已完结
Bridging the Gap: Integrating Quantitative Systems Pharmacology and Pharmacometrics in Drug Development
1个月前
已完结
Fibroblast Growth Factor Receptor 4 (FGFR4) Selective Inhibitors as Hepatocellular Carcinoma Therapy: Advances and Prospects
1个月前
已完结
Daraxonrasib for Previously Treated RAS -Mutant Non–Small-Cell Lung Cancer
1个月前
已完结
Daraxonrasib in Previously Treated Advanced RAS -Mutated Pancreatic Cancer
3个月前
已完结
皖公网安备34019202002308
